Trajectory of migraine-related disability following long-term treatment with lasmiditan: results of the GLADIATOR study

Autor: Richard B. Lipton, Louise Lombard, Dustin D. Ruff, John H. Krege, Li Shen Loo, Andrew Buchanan, Thomas E. Melby, Dawn C. Buse

Publikováno v: The Journal of Headache and Pain, Vol 21, Iss 1, Pp 1-15 (2020)

Abstract Background Migraine is recognized as the second leading cause of disability globally. Lasmiditan is a novel, selective serotonin 5-HT1F receptor agonist developed for acute treatment of migraine. Here we analyzed effects of lasmiditan on mig

Externí odkaz: https://doaj.org/article/da23bbe9f2134bc4a0a5ebd3697602f8

Longitudinal Effects of Teriparatide or Zoledronic Acid on Bone Modeling- and Remodeling-Based Formation in the SHOTZ Study

Autor: Jahangir Alam, Valerie A Ruff, Thomas E. Melby, David W. Dempster, Kathleen A. Taylor, Hua Zhou

Publikováno v: Journal of Bone and Mineral Research. 33:627-633

Previously, we reported on bone histomorphometry, biochemical markers, and bone mineral density distribution after 6 and 24 months of treatment with teriparatide (TPTD) or zoledronic acid (ZOL) in the SHOTZ study. The study included a 12-month primar

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::137744f2f3bd0a65526bafc66ba29711
https://doi.org/10.1002/jbmr.3350

Reduction of Hip and Other Fractures in Patients Receiving Teriparatide in Real-World Clinical Practice: Integrated Analysis of Four Prospective Observational Studies

Autor: Stuart L. Silverman, John H. Krege, Bente L. Langdahl, Nicola Napoli, Kenneth G. Saag, Satoshi Soen, Hiroyuki Enomoto, Fernando Marin, Damon Disch, Thomas E. Melby, Saeko Fujiwara

Publikováno v: Silverman, S, Langdahl, B L, Fujiwara, S, Saag, K, Napoli, N, Soen, S, Enomoto, H, Melby, T E, Disch, D P, Marin, F & Krege, J H 2019, ' Reduction of Hip and Other Fractures in Patients Receiving Teriparatide in Real-World Clinical Practice: Integrated Analysis of Four Prospective Observational Studies ', Calcified Tissue International, vol. 104, no. 2, pp. 193-200 . https://doi.org/10.1007/s00223-018-0485-2

The phase 3 teriparatide Fracture Prevention Trial showed significant reductions in vertebral (VF) and nonvertebral (NVF) fractures; however, patient exposure was insufficient for full analysis of low-incidence fractures, including hip. We assessed f

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74e8b3cf26f15275e75945563b0da8be
https://pure.au.dk/portal/da/publications/reduction-of-hip-and-other-fractures-in-patients-receiving-teriparatide-in-realworld-clinical-practice-integrated-analysis-of-four-prospective-observational-studies(504916a7-c17e-42e4-8e7a-9f80ec046a82).html

Remodeling- and Modeling-Based Bone Formation With Teriparatide Versus Denosumab: A Longitudinal Analysis From Baseline to 3 Months in the AVA Study

Autor: David W, Dempster, Hua, Zhou, Robert R, Recker, Jacques P, Brown, Christopher P, Recknor, E Michael, Lewiecki, Paul D, Miller, Sudhaker D, Rao, David L, Kendler, Robert, Lindsay, John H, Krege, Jahangir, Alam, Kathleen A, Taylor, Thomas E, Melby, Valerie A, Ruff

Publikováno v: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 33(2)

There has been renewed interest of late in the role of modeling-based formation (MBF) during osteoporosis therapy. Here we describe early effects of an established anabolic (teriparatide) versus antiresorptive (denosumab) agent on remodeling-based fo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::999624e25038cb36483b01a32b7408fb
https://pubmed.ncbi.nlm.nih.gov/29024120

Resistance to Enfuvirtide and Other HIV Entry Inhibitors

Autor: Michael L. Greenberg, Thomas E. Melby, Gabrielle Heilek, Nick Cammack

Publikováno v: Antimicrobial Drug Resistance ISBN: 9781603275927

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::caf5f65c18a9ad074611477efc855505
https://doi.org/10.1007/978-1-59745-180-2_35